246 related articles for article (PubMed ID: 37288137)
1. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
El-Ghazzi N; Durando X; Giro A; Herrmann T
Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
[TBL] [Abstract][Full Text] [Related]
2. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
[TBL] [Abstract][Full Text] [Related]
3. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
[TBL] [Abstract][Full Text] [Related]
4. How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review.
Maiorano BA; Maiorano MFP; Cormio G; Maglione A; Lorusso D; Maiello E
Front Oncol; 2022; 12():844801. PubMed ID: 35494078
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue "Diagnosis and Management of Endometrial Cancer".
Gadducci A; Cosio S
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944775
[TBL] [Abstract][Full Text] [Related]
6. Biomarker-driven therapy in endometrial cancer.
Karpel H; Slomovitz B; Coleman RL; Pothuri B
Int J Gynecol Cancer; 2023 Mar; 33(3):343-350. PubMed ID: 36878569
[TBL] [Abstract][Full Text] [Related]
7. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
[TBL] [Abstract][Full Text] [Related]
8. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
[TBL] [Abstract][Full Text] [Related]
9. A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer.
Tinker AV; Dhani NC; Ghatage P; McLeod D; Samouëlian V; Welch SA; Altman AD
Ther Adv Med Oncol; 2023; 15():17588359231157633. PubMed ID: 36950270
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
12. Treatment options for molecular subtypes of endometrial cancer in 2023.
Karpel HC; Slomovitz B; Coleman RL; Pothuri B
Curr Opin Obstet Gynecol; 2023 Jun; 35(3):270-278. PubMed ID: 36943683
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 Pathway in Advanced, Recurrent Endometrial Cancer: A Scoping Review with SWOT Analysis.
Johnson RL; Ganesan S; Thangavelu A; Theophilou G; de Jong D; Hutson R; Nugent D; Broadhead T; Laios A; Cummings M; Orsi NM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760602
[TBL] [Abstract][Full Text] [Related]
15. Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series.
Rose PG; Feldman M; Podzielinski I; Petty AP; Vargas R
Gynecol Oncol Rep; 2023 Dec; 50():101303. PubMed ID: 38054201
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.
O'Malley DM; Bariani GM; Cassier PA; Marabelle A; Hansen AR; De Jesus Acosta A; Miller WH; Safra T; Italiano A; Mileshkin L; Xu L; Jin F; Norwood K; Maio M
J Clin Oncol; 2022 Mar; 40(7):752-761. PubMed ID: 34990208
[TBL] [Abstract][Full Text] [Related]
17. Old Issues and New Perspectives on Endometrial Cancer Therapy: How Molecular Characteristics Are Changing the Therapeutic Pathway.
Luvero D; Cundari GB; Ficarola F; Plotti F; Terranova C; Montera R; Bogani G; Silvagni A; Celoro F; Angioli R
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791945
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
[TBL] [Abstract][Full Text] [Related]
20. A Review of Immune Checkpoint Blockade Therapy in Endometrial Cancer.
Green AK; Feinberg J; Makker V
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-7. PubMed ID: 32213091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
